Advanced search×

Novel Agents and Future Directions for Refractory Breast Cancer

Harold J Burstein

Semin Oncol (2011) PMID 21600381

Tumor resistance remains a major clinical challenge. Numerous pathways are under investigation to determine how best to target therapies to specific mutations in tumor biology and circumvent resistance. Agents in development include inhibitors of the poly(adenosine diphosphate [ADP]-ribose) polymerase (PARP) pathway, such as iniparib, olaparib, and veliparib; the PI3K/Akt/mTOR pathway inhibitor everolimus; and the Src family tyrosine kinase inhibitor dasatinib. Research is ongoing to determine whether patients with specific biochemical attributes, such as the presence of a BRCA1 or BRCA2 mutation, will have a better response to targeted therapy and whether targeted agents act synergistically with chemotherapeutic agents.

Copyright © 2011 Elsevier Ltd. All rights reserved.

DOI: 10.1053/j.seminoncol.2011.04.002
Version: za2963e q8za0 q8zb3 q8zce q8zd8 q8ze0 q8zfb q8zge

Similar articles you may find interesting…

  1. The ribonucleotide reductase large subunit (RRM1) as a predictive factor in patients with cancer.
    Lars Petter Jordheim, Pascal Sève, ... Charles Dumontet

    Lancet Oncol 12(7):693-702 (2011) PMID 21163702

    We review preclinical and clinical studies of RRM1 assessment and discuss the further steps in the development of this clinically pertinent biomarker. Copyright © 2010 Elsevier Ltd. All rights reserved....
  2. Anthracycline- and/or taxane-resistant breast cancer: Results of a literature review to determine the clinical challenges and current treatm...
    Alvaro Moreno-Aspitia and Edith A Perez

    Clin Ther 31(8):1619-1640 (2009) PMID 19808124

    As many as 30% of women diagnosed with early breast cancer (BC) will eventually progress to or relapse with locally advanced or meta-static BC. Resistance to the commonly used chemotherapies anthracyclines and taxanes, as well as the approval of new pharmacologic options for treating...
  3. Molecular portraits of human breast tumours.
    C M CM Perou, T T Sørlie, ... D D Botstein

    Nature 406(6797):747-52 (2000) PMID 10963602

    We have characterized variation in gene expression patterns in a set of 65 surgical specimens of human breast tumours from 42 different individuals, using complementary DNA microarrays representing 8,102 human genes. These patterns provided a distinctive molecular portrait of each tumour. Twenty of...